Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

SPARTA technology to accelerate the development, manufacture and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs.

Thermo Fisher Scientific TSX and TDE Series ultra-low freezers are tested according to ISO 14644-14 and designated ISO Class 5.5; operational; 0.1 μm, 0.2 μm, 0.3 μm, 0.5 μm, 1.0 μm, contributing to the safe and effective development of therapies.

Under the new agreement, Integrated DNA Technologies (IDT) will sell Aldevron cGMP-manufactured CRISPR nucleases to enable customers to rapidly transition from discovery to clinic.

Form Bio, announced capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates.

Ganymede Bio and Kytopen have announced a partnership to bring the power of cloud-native, structured data to Kytopen’s Flowfect® platforms.

Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.